


CLAIMS

What is claimed is:

1. A compound of Formula I:



wherein:

A is C(R⁵) or N;

R⁵ is H, C₁₋₃ alkyl, CN or halogen;


R² is 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl;

optionally substituted with one to three substituents independently

selected from the group consisting of R¹⁰, OR¹⁰, SR¹⁰, S(O)R¹⁰, S(O)₂R¹⁰, C(O)R¹⁰, C(O)OR¹⁰, OC(O)R¹⁰, OC(O)OR¹⁰, NH₂, NH R¹⁰, N(R¹⁰)₂, NHC(O)H, NHC(O)R¹⁰, N R¹⁰C(O)H, N R¹⁰C(O)R¹⁰, NHS(O)₂R¹⁰, N R¹⁰S(O)₂R¹⁰, NHC(O)OR¹⁰, N R¹⁰C(O)OR¹⁰, NHC(O)NH₂, NHC(O)NH R¹⁰, NHC(O)N(R¹⁰)₂, N R¹⁰C(O)NH₂, N R¹⁰C(O)NH R¹⁰, N R¹⁰C(O)N(R¹⁰)₂, C(O)NH₂, C(O)NH R¹⁰, C(O)N(R¹⁰)₂, C(O)NHOH, C(O)NHO R¹⁰, C(O)NHS(O)₂R¹⁰, C(O)N R¹⁰S(O)₂R¹⁰, S(O)₂NH₂, S(O)₂NH R¹⁰, S(O)₂N(R¹⁰)₂, S(O)₂NHC(O)OR¹⁰, S(O)₂N R¹⁰C(O)OR¹⁰, C(O)H, C(O)OH, OH, CN, NO₂, F, Cl, Br and I; , wherein one or more ring CH₂ groups can optionally be replaced by a corresponding number of -C(O) groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides;

R¹⁰, at each occurrence, is independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C₁₋₆ alkyl, -O- C₁₋₆ alkyl, C₁₋₆ alkyl-O- C₁₋₆ alkyl, NH₂, C(O)NH₂, C(O)H, C(O)OH, OH, CN, NO₂, F, Cl, Br and I; wherein two R¹⁰ groups together with the atoms to which they are attached may form a 3 to 6 membered cycloalkyl or heterocycloalkyl group; and each aforementioned R¹⁰ alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from

CN, OH, halogen, C₁₋₃ alkyl, -O-C₁₋₃ alkyl, NH₂, NH-C₁₋₃ alkyl, and NHC(O)-C₁₋₃ alkyl.



wherein X and Y together with the atoms to which they are attached, form a 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S, which ring may be saturated or partially saturated; wherein one or two ring CH₂ groups can optionally be replaced by a corresponding number of -C(O) groups, one or more ring sulfur or nitrogen atoms may be optionally oxidized to form S-oxides or N-oxides and wherein the ring may be substituted on a ring carbon by one or two R¹⁰ substituents or on a ring nitrogen by an R¹² substituent.


J is N or CR¹¹; and

R¹¹ is H, C₁₋₃ alkyl;

R¹² is at each occurrence independently selected from the group consisting of a 3 to 6 membered cycloalkyl or heterocycloalkyl group, C₁₋₆ alkyl, C₁₋₆ alkyl-O-C₁₋₆ alkyl, C(O)NH₂, C(O)H; wherein R¹² alkyl, cycloalkyl and heterocycloalkyl group may be further substituted with one or two substituents independently selected from CN, OH, and halogen, C₁₋₃ alkyl, NH₂, and NH-C₁₋₃ alkyl, NHC(O)-C₁₋₃ alkyl, or pharmaceutical acceptable salts thereof.

2. The compound of Claim 1 wherein **A** is C(R⁵).
3. The compound of Claim 2 wherein R⁵ is chloro.
4. The compound of Claim 2 wherein R⁵ is fluoro.
5. The compound of Claim 1 wherein R² is a 3-7 membered cycloalkyl.
6. The compound of Claim 1 wherein R² is 3-7 membered cycloalkyl substituted with NHCOR¹⁰ or R¹⁰.
7. The compound of Claim 6 wherein R² is selected from the group cyclopropyl,

cocyllobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

8. The compound of Claim 7 wherein R^2 is selected from the cyclopentyl and cyclohexyl.
 9. The compound of Claim 8 wherein R^2 is cyclohexyl substituted with $NHCOR^{10}$.
 10. The compound of Claim 1 wherein R^2 is 3-7 membered heterocycloalkyl.
 11. The compound of Claim 10 wherein R^2 is 3-7 membered heterocycloalkyl substituted with $NHCOR^{10}$.
- piperidine
- 
12. The compound of Claim 1 wherein R_4 is .
 13. The compound of Claim 12 wherein J is $C(R^{11})$.
 14. The compound of Claim 13 wherein R^{11} is H.
 15. The compound of Claim 1 wherein **X** and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.
 16. The compound of Claim 15 wherein **X** and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring containing an additional heteroatom which is oxygen.
 17. The compound of Claim 15 wherein **X** and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring containing an additional heteroatom

which is nitrogen.

18. The compound of Claim 1 wherein **X** and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.


19. The compound of Claim 18 wherein **X** and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring in which one CH₂ is substituted with two methyl groups.

20. The compound of Claim 1 wherein **X** and **Y** together with the atoms to which they are attached form a 7 membered heterocycloalkyl ring.

21. The compound of Claim 1 wherein:

A is C(R⁵);

R² is 3-7 membered cycloalkyl;

R⁴ is ; and

X and **Y** together with the atoms to which they are attached form a 6 membered


heterocycloalkyl ring.

22 The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is halogen;

R² is 3-7 membered cycloalkyl;




X and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.

23. The compound of Claim 22 wherein

A is C(R⁵);

R⁵ is chloro;

R² is 3-7 membered cycloalkyl;



X and **Y** together with the atoms to which they are attached form a 6 membered


heterocycloalkyl ring.

24. The compound of Claim 22 wherein

A is C(R⁵);

R⁵ is fluoro;

R² is 3-7 membered cycloalkyl;




X and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.

25. The compound of Claim 1 wherein:

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl ;




X and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.

26. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is halogen;

R² is 3-7 membered cycloalkyl;




X and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

27. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is halogen;

R² is cyclohexyl




X and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

28. The compound of Claim 27 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl;




X and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.

29. The compound of Claim 1 wherein:

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;




X and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.

30. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;



X and **Y** together with the atoms to which they are attached form a 5 membered

heterocycloalkyl ring.


31. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;

R¹⁰ is C₁₋₆ alkyl;



J is C(R¹¹) and R¹¹ is H;

and

X and **Y** together with the atoms to which they are attached form a 6 membered heterocycloalkyl ring.


32. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;

R¹⁰ is C₁₋₆ alkyl;



J is C(R¹¹) and R¹¹ is H;

and

X and **Y** together with the atoms to which they are attached form a 5 membered heterocycloalkyl ring.


33. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;

R¹⁰ is C₁₋₆ alkyl;



J is C(R¹¹) and R¹¹ is H

and

X and **Y** together with the atoms to which they are attached form a piperidinyl ring.


34. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;

R¹⁰ is C₁₋₆ alkyl;



J is C(R¹¹) and R¹¹ is H

and

X and **Y** together with the atoms to which they are attached form a piperazinyl ring.


35. The compound of Claim 1 wherein

A is C(R⁵);

R⁵ is chloro;

R² is cyclohexyl substituted with NHC(O)R¹⁰ ;

R^{10} is C_{1-6} alkyl;



J is $C(R^{11})$ and R^{11} is H
and

X and Y together with the atoms to which they are attached form a morpholinyl ring.


36. The compound of Claim 1 wherein

A is $C(R^5)$;

R^5 is chloro;

R^2 is cyclohexyl substituted with $NHC(O)R^{10}$;

R^{10} is C_{1-6} alkyl;



J is $C(R^{11})$ and R^{11} is H
and

X and Y together with the atoms to which they are attached form a pyrrolidinyl wherein one CH_2 is substituted with two methyl groups.

37. A compound selected from:

(R)-N-(5-chloro-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)pyridin-2-yl)piperidine-3-carboxamide;

(1S,3R)-3-acetamido-N-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-N-(4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Cis-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)-3-hydroxycyclobutanecarboxamide;
 (R)-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)piperidine-3-carboxamide;
 cis-3-hydroxy-*N*-(4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclobutanecarboxamide ;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1R,3S)-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (1S,3R)-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)-3-(1-hydroxycyclopropanecarboxamido)cyclohexanecarboxamide;
N-((1R,3S)-3-((4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)carbamoyle)cyclohexyl)oxetane-3-carboxamide;

N-((1*R*,3*S*)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)oxetane-3-carboxamide;
 (1*S*,3*R*)-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)-3-((*S*)-2-hydroxypropanamido)cyclohexanecarboxamide;
 (1*S*,3*R*)-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)-3-(1-hydroxycyclopropanecarboxamido)cyclohexanecarboxamide;
 (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(6,6-dimethyl-6,7-dihydro-5*H*-pyrrolo[1,2-*a*]imidazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;
 (*R*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-3-carboxamide;
 (*S*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-3-carboxamide;
 (1*S*,3*R*)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide;
cis-N-(4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)-3-hydroxycyclobutanecarboxamide;
cis-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)-3-hydroxycyclobutanecarboxamide;
 (1*S*,3*R*)-3-acetamido-*N*-(6-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-4-yl)cyclohexanecarboxamide;
trans-3-hydroxy-*N*-(6-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyrimidin-4-yl)cyclobutanecarboxamide;
 (1*S*,3*R*)-3-acetamido-*N*-(6-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyrimidin-4-yl)cyclohexanecarboxamide;
 (1*S*,3*R*)-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)-3-(2-cyanoacetamido)cyclohexanecarboxamide;
tert-butyl ((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate;
 (1*S*,3*R*)-3-amino-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)-3-(1-hydroxycyclopropanecarboxamido)cyclohexanecarboxamide;

(*R*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-3-carboxamide;

N-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)-3-methyloxetane-3-carboxamide;

(*S*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-2-carboxamide;

(*R*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-2-carboxamide;

(1*S*,3*R*)-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)-3-((*S*)-2-hydroxypropanamido)cyclohexanecarboxamide;

(*S*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-3-carboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(5-cyano-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*R*,3*S*)-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(*S*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-2-carboxamide;

(*R*)-*N*-((1*R*,3*S*)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)tetrahydrofuran-2-carboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-methylpyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclopentanecarboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydro-[1,2,3] triazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(4-(6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-amino-*N*-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)-3-(3-hydroxypropanamido)cyclohexanecarboxamide;

(1S,3R)-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)-3-(cis-3-hydroxycyclobutanecarboxamido)cyclohexanecarboxamide

(1S,3R)-3-amino-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexane-1-carboxamide;

(1S,3R)-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl)-3-(1-hydroxycyclopropanecarboxamido)cyclohexanecarboxamide;

(1S,3R)-*N*-(5-chloro-4-(6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl)-3-(1-hydroxycyclopropanecarboxamido)cyclohexanecarboxamide;

N-((1R,3S)-3-((5-chloro-4-(6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)oxetane-3-carboxamide;

cis-N-(5-chloro-4-(6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyridin-2-yl)-3-hydroxycyclobutanecarboxamide;

Isomer 1 of trans-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of trans-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of trans-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of trans-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(5-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5,6,7,8-tetrahydro-4*H*-pyrazolo[1,5-*a*]azepin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

N-((1*R*,3*S*)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)oxetane-3-carboxamide;

Isomer 1 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(6-methyl-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(6-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(6-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1*S*,3*R*)-3-acetamido-*N*-(5-chloro-4-(5-methoxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*S*,3*R*)-3-acetamido-*N*-(5-fluoro-4-(5,6,7,8-tetrahydro-4*H*-pyrazolo[1,5-*a*]azepin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1*S*,3*R*)-*N*-(4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-methylpyridin-2-yl)-3-(2-hydroxyacetamido)cyclohexanecarboxamide;

N-((1*R*,3*S*)-3-((4-(5,5-dimethyl-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-methylpyridin-2-yl)carbamoyl)cyclohexyl)oxetane-3-carboxamide;

(1S,3R)-3-acetamido-*N*-(5-methyl-4-(4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(7-hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(5-(4-hydroxybutyl)-1H-pyrazol-4-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 1 of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(4-hydroxy-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

Isomer 2 of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(4-hydroxy-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide;

(1R,3S)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(5-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1-carboxamide;

(1S,3R)-3-acetamido-*N*-(5-chloro-4-(6-hydroxy-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)pyridin-2-yl)cyclohexane-1-carboxamide;

(1R,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexane-1-carboxamide; and

(1S,3S)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexane-1-carboxamide, or a pharmaceutically acceptable salt thereof.

38. A crystalline form of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide.

39. A crystalline form of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide characterized by specific peaks at 2-theta = 5.5, 6.8, 13.6, 16.1, 20.5, 21.2, 21.6, 22.8, 26.7, 27.4° in its X-ray powder diffractogram.

40. A crystalline form of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide.

41. A crystalline form of (1S,3R)-3-acetamido-*N*-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide characterized by specific peaks at 2-theta = 5.9, 7.0, 9.4, 10.5, 11.5, 11.7, 17.6, 18.0, 20.2 and 21.0° in its X-ray powder diffractogram.

42. A crystalline form of (1S,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide.

43. A crystalline form of (1S,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide characterized by specific peaks at 2-theta = 8.8, 10.1, 11.5, 18.9, 20.0, 20.5, 21.8, 22.8, 23.9 and 25.2° in its X-ray powder diffractogram.

44. A crystalline form of (1S,3R)-3-acetamido-*N*-(4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide characterized by specific peaks at 2-theta = 8.3, 11.0, 13.1, 16.6, 19.4, 20.4, 22.3, 27.0, 27.2 and 28.6 °and 25.2° in its X-ray powder diffractogram.

45. A pharmaceutical composition containing a compound of any one of Claims 1-44.

46. Use of the compound of any one of claims 1 to 44 in the manufacture of a medicament for the treatment of cancer, wherein an effective amount of the medicament is to be administered to a subject suffering from cancer.

47. A compound of any one of claims 1 to 44 for use in the treatment of cancer, wherein an effective amount of the medicament is to be administered to a subject suffering from cancer.